Back to Agenda
Opening Plenary and Keynote Address
Session Chair(s)
Marwan Fathallah, MBA, MSC
President & Chief Executive Officer, DIA, United States
Join our opening plenary session, Innovation: The Possibilities, The Boundaries: Charting New Horizons, led by Tom and Emily Whitehead, who will give the incredible journey of Emily Whitehead, the pioneering pediatric patient who defied the odds and became the first in the world to undergo CAR T-cell therapy. Tom and Emily will share their invaluable insights into the transformative power of CAR-T therapy, offering a unique perspective that promises to captivate and inspire. Dean Kamen will discuss the Future of Regenerative Therapies, How Public-Private Partnerships Can Impact Advancement. Following your keynotes, we will have a panel discussion. Attendees can expect a lively and engaging discussion, with a diverse range of perspectives and insights from panelists who are leaders and at the forefront of our industry; including panelists from the Gates Foundation, regulatory agencies, and the patient perspective.
Speaker(s)
Carsten Linnermann, PHD
Chief Executive Officer, Neogene Therapeutics, AstraZeneca Group, Netherlands
Developing Cell Therapies for Cancer Patients
Tom Whitehead
Co-Founder and President, Emily Whitehead Foundation, United States
Keynote Speaker: Insights into the Transformative Power of CAR-T Therapy
Emily Whitehead
Co-Founder, Emily Whitehead Foundation, United States
Keynote Speaker: Insights into the Transformative Power of CAR-T Therapy
Dean Kamen
Founder , DEKA Research & Development Corp., United States
Keynote Speaker: Future of Regenerative Therapies - How Public-Private Partnerships Can Impact Advancement
David Mukanga, PHD, MPH
Deputy Director, Africa Regulatory Systems, Bill & Melinda Gates Foundation, United States
Plenary Panel: Innovation - The Possibilities, the Boundaries - Charting New Horizons
Dean Kamen
Founder , DEKA Research & Development Corp., United States
Panelist: Innovation
Emer Cooke, MBA
Executive Director, European Medicines Agency, Netherlands
Panelist: EMA Perspective
Peter Marks, MD, PHD
Senior Vice President, Molecule Discovery and Head of Infectious Disease, Eli Lilly and Company, United States
Panelist: FDA Perspective
Stacy Hurt, MBA, MHA
Chief Patient Officer, Parexel International, United States
Panelist: Patient Perspective
Have an account?